Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 study of GS-5718​ for the treatment of inflammatory bowel disease

Trial Profile

A Phase 1 study of GS-5718​ for the treatment of inflammatory bowel disease

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Edecesertib (Primary) ; Omeprazole
  • Indications Cutaneous lupus erythematosus; Inflammatory bowel diseases; Rheumatoid arthritis; Systemic lupus erythematosus
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 18 Mar 2022 Results of population pharmacokinetics of GS-5718 in healthy subjects presented at the 123rd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 09 Nov 2021 Results presented at the ACR Convergence 2021
    • 05 Jun 2021 Status changed from recruiting to completed as per results presented at the 22nd Annual Congress of the European League Against Rheumatism
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top